According to current guidelines, kidney biopsy should be performed where possible, however, in the context of positive MPO- or PR3-ANCA serology and a clinical picture compatible with AAV, an immediate biopsy may not be necessary and should not delay the initiation of treatment (73, 119). The gene discussed is PRTN3; the disease is anti-neutrophil cytoplasmic antibody-associated vasculitis.